Preeclampsia affects 3–5% of pregnancies and can have a significant impact on health for both mother and fetus. Risk factors include maternal co-morbidities such as obesity and chronic hypertension, paternal factors, and genetic factors. New hypertension and proteinuria during the second half of pregnancy are key diagnostic criteria, but the clinical features and associated prognostic implications are somewhat heterogeneous and may reflect different mechanisms of disease. Renal dysfunction and proteinuria correspond to the pathologic finding of glomerular endotheliosis, and generally resolve after cure of preeclampsia through fetal and placenta delivery. The molecular mechanisms behind this disease are being discovered and refined. The initial etiologic agents are currently unknown. Pathologic studies show abnormal development of an ischemic placenta with a high-resistance vasculature, which cannot deliver an adequate blood supply to the fetoplacental unit. Endothelial dysfunction plays a central role in the pathogenesis of the maternal syndrome. Dysfunctional endothelial cells produce altered quantities of vasoactive mediators, which lead to a tip in the balance towards vasoconstriction. An imbalance in circulating angiogenic factors is emerging as a prominent mechanism that mediates the endothelial dysfunction and the clinical signs and symptoms of preeclampsia. Soluble fms-like tyrosine kinase 1 (sFlt1), an endogenous anti-angiogenic factor that is a potent vascular endothelial growth factor (VEGF) antagonist, is highly elevated in preeclampsia. VEGF is not only important in angiogenesis, but also in maintaining endothelial health including the formation of endothelial fenestrae (a hallmark of the glomerular vascular endothelium). sFlt1 overexpression in animals induces glomerular endotheliosis with the loss of endothelial fenestrae that resembles the renal histological lesions of preeclampsia. More severe forms of preeclampsia, including the HELLP syndrome, may be explained by a concomitant elevation in both sFlt1 and soluble endoglin, another anti-angiogenic factor. Unraveling of the molecular mechanisms behind preeclampsia may help to expand our armamentarium to treat patients in a more directed fashion, as current management consists of supportive care and expedited delivery. Finally, long-term outcomes of women with preeclampsia include a significantly increased risk for hypertension and cardiovascular disease, including mortality, which may warrant more aggressive screening and treatment in this population.

Keywords:
Hypertension, Proteinuria, Angiogenesis, Vascular endothelial growth factor, Endotheliosis
1.
Pregnancy: Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183:S1–S22.
2.
Stella CL, Sibai BM: Preeclampsia: diagnosis and management of the atypical presentation. J Matern Fetal Neonatal Med 2006;19:381–386.
3.
Buchbinder A, Sibai BM, Caritis S, Macpherson C, Hauth J, Lindheimer MD, Klebanoff M, Vandorsten P, Landon M, Paul R, Miodovnik M, Meis P, Thurnau G: Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol 2002;186:66–71.
4.
Lachmeijer AM, Dekker GA, Pals G, Aarnoudse JG, ten Kate LP, Arngrimsson R: Searching for preeclampsia genes: the current position. Eur J Obstet Gynecol Reprod Biol 2002;105:94–113.
5.
Thadhani R, Stampfer MJ, Hunter DJ, Manson JE, Solomon CG, Curhan GC: High body mass index and hypercholesterolemia: risk of hypertensive disorders of pregnancy. Obstet Gynecol 1999;94:543–550.
6.
Said J, Dekker G: Pre-eclampsia and thrombophilia. Best Pract Res Clin Obstet Gynaecol 2003;17:441–458.
7.
Xiong X, Wang FL, Davidge ST, Demianczuk NN, Mayes DC, Olson DM, Saunders LD: Maternal smoking and preeclampsia. J Reprod Med 2000;45:727–732.
8.
Schobel HP, Fischer T, Heuszer K, Geiger H, Schmieder RE: Preeclampsia – a state of sympathetic overactivity. N Engl J Med 1996;335:1480–1485.
9.
Chesley LC, Talledo E, Bohler CS, Zuspan FP: Vascular reactivity to angiotensin II and norepinephrine in pregnant women. Am J Obstet Gynecol 1965;91:837–842.
10.
Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC: A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973;52:2682–2689.
11.
AbdAlla S, Lother H, el Massiery A, Quitterer U: Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001;7:1003–1009.
12.
Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC: Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999;103:945–952.
13.
Shah DM: Role of the renin-angiotensin system in the pathogenesis of preeclampsia. Am J Physiol 2005;288:F614–F625.
14.
Baker PN, Davidge ST, Barankiewicz J, Roberts JM: Plasma of preeclamptic women stimulates and then inhibits endothelial prostacyclin. Hypertension 1996;27:56–61.
15.
Mills JL, DerSimonian R, Raymond E, Morrow JD, Roberts LJ 2nd, Clemens JD, Hauth JC, Catalano P, Sibai B, Curet LB, Levine RJ: Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. JAMA 1999;282:356–362.
16.
Clark BA, Halvorson L, Sachs B, Epstein FH: Plasma endothelin levels in preeclampsia: elevation and correlation with uric acid levels and renal impairment. Am J Obstet Gynecol 1992;166:962–968.
17.
Williams DJ, Vallance PJ, Neild GH, Spencer JA, Imms FJ: Nitric oxide-mediated vasodilation in human pregnancy. Am J Physiol 1997;272:H748–H752.
18.
Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS: Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001;285:1607–1612.
19.
Davison JM, Dunlop W: Renal hemodynamics and tubular function normal human pregnancy. Kidney Int 1980;18:152–161.
20.
Lafayette RA, Druzin M, Sibley R, Derby G, Malik T, Huie P, Polhemus C, Deen WM, Myers BD: Nature of glomerular dysfunction in pre-eclampsia. Kidney Int 1998;54:1240–1249.
21.
Mautner W, Churg J, Grishman E, Dachs S: Preeclamptic nephropathy. An electron microscopic study. Lab Invest 1962;11:518–530.
22.
Moran P, Baylis PH, Lindheimer MD, Davison JM: Glomerular ultrafiltration in normal and preeclamptic pregnancy. J Am Soc Nephrol 2003;14:648–652.
23.
Pollak VE, Nettles JB: The kidney in toxemia of pregnancy: a clinical and pathologic study based on renal biopsies. Medicine (Baltimore) 1960;39:469–526.
24.
Spargo B, McCartney CP, Winemiller R: Glomerular capillary endotheliosis in toxemia of pregnancy. Arch Pathol 1959; 68: 593–599.
25.
Strevens H, Wide-Swensson D, Hansen A, Horn T, Ingemarsson I, Larsen S, Willner J, Olsen S: Glomerular endotheliosis in normal pregnancy and pre-eclampsia. Br J Obstet Gynaecol 2003;110:831–836.
26.
Ballermann BJ: Glomerular endothelial cell differentiation. Kidney Int 2005;67:1668–1671.
27.
Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707–716.
28.
Heaton JM, Turner DR: Persistent renal damage following pre-eclampsia: a renal biopsy study of 13 patients. J Pathol 1985;147:121–126.
29.
Brown MA, Zammit VC, Lowe SA: Capillary permeability and extracellular fluid volumes in pregnancy-induced hypertension. Clin Sci (Lond) 1989;77:599–604.
30.
Orloff J, Welt LG, Stowe L: The effects of concentrated salt-poor albumin on the metabolism and excretion of water and electrolytes in nephrosis and toxemia of pregnancy. J Clin Invest 1950;29:770–780.
31.
Slemmons JBL: The uric acid content of maternal and fetal blood. J Biol Chem 1917;32:63–69.
32.
Redman CW, Bonnar J: Plasma urate changes in pre-eclampsia. Br Med J 1978;i:1484–1485.
33.
Nochy D, Birembaut P, Hinglais N, Freund M, Idatte JM, Jacquot C, Chartier M, Bariety J: Renal lesions in the hypertensive syndromes of pregnancy: immunomorphological and ultrastructural studies in 114 cases. Clin Nephrol 1980;13:155–162.
34.
Martin JN Jr, May WL, Magann EF, Terrone DA, Rinehart BK, Blake PG: Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity. Am J Obstet Gynecol 1999;180:1407–1414.
35.
Sagen N, Haram K, Nilsen ST: Serum urate as a predictor of fetal outcome in severe pre-eclampsia. Acta Obstet Gynecol Scand 1984;63:71–75.
36.
Thangaratinam S, Ismail KM, Sharp S, Coomarasamy A, Khan KS: Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. Br J Obstet Gynaecol 2006;113:369–378.
37.
Powers RW, Bodnar LM, Ness RB, Cooper KM, Gallaher MJ, Frank MP, Daftary AR, Roberts JM: Uric acid concentrations in early pregnancy among preeclamptic women with gestational hyperuricemia at delivery. Am J Obstet Gynecol 2006;194:160.
38.
Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101–1106.
39.
Schwartz RB, Feske SK, Polak JF, DeGirolami U, Iaia A, Beckner KM, Bravo SM, Klufas RA, Chai RY, Repke JT: Preeclampsia-eclampsia: clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. Radiology 2000;217:371–376.
40.
Kaplan PW: The neurologic consequences of eclampsia. Neurologist 2001;7:357–363.
41.
Purkerson ML, Vekerdy L: A history of eclampsia, toxemia and the kidney in pregnancy. Am J Nephrol 1999;19:313–319.
42.
van Pampus MG, Aarnoudse JG: Long-term outcomes after preeclampsia. Clin Obstet Gynecol 2005;48:489–494.
43.
Baxter JK, Weinstein L: HELLP syndrome: the state of the art. Obstet Gynecol Surv 2004;59:838–845.
44.
Taylor RN, Crombleholme WR, Friedman SA, Jones LA, Casal DC, Roberts JM: High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. Am J Obstet Gynecol 1991;165:895–901.
45.
Friedman SA, Schiff E, Emeis JJ, Dekker GA, Sibai BM: Biochemical corroboration of endothelial involvement in severe preeclampsia. Am J Obstet Gynecol 1995;172:202–203.
46.
Hsu CD, Iriye B, Johnson TR, Witter FR, Hong SF, Chan DW: Elevated circulating thrombomodulin in severe preeclampsia. Am J Obstet Gynecol 1993;169:148–149.
47.
Estelles A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR: Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989;74:1332–1338.
48.
Page E: The relation between hydatid moles, relative ischemia of the gravid uterus and the placental origin of eclampsia. Am J Obstet Gynecol 1939;37:291–293.
49.
Redman CW, Sargent IL: Latest advances in understanding preeclampsia. Science 2005;308:1592–1594.
50.
Brosens IA, Robertson WB, Dixon HG: The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1972;1:177–191.
51.
De Wolf F, De Wolf-Peeters C, Brosens I, Robertson WB: The human placental bed: electron microscopic study of trophoblastic invasion of spiral arteries. Am J Obstet Gynecol 1980;137:58–70.
52.
Zhou Y, Damsky CH, Fisher SJ: Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997;99:2152–2164.
53.
Robertson WB, Brosens I, Dixon HG: The pathological response of the vessels of the placental bed to hypertensive pregnancy. J Pathol Bacteriol 1967;93:581–592.
54.
Hubel CA, McLaughlin MK, Evans RW, Hauth BA, Sims CJ, Roberts JM: Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 48 hours post partum. Am J Obstet Gynecol 1996;174:975–982.
55.
Kolben M, Lopens A, Blaser J, Huber A, Frank M, Wilhelm O, Wilhelm S, Schneider KT, Ulm K, Tschesche H, et al: Measuring the concentration of various plasma and placenta extract proteolytic and vascular factors in pregnant patients with HELLP syndrome, pre-/eclampsia and highly pathologic Doppler flow values. Gynaekol Geburtsh Rundsch 1995;35(suppl 1):126–131.
56.
Davidge ST: Oxidative stress and altered endothelial cell function in preeclampsia. Semin Reprod Endocrinol 1998;16:65–73.
57.
Lockwood CJ, Peters JH: Increased plasma levels of ED1+ cellular fibronectin precede the clinical signs of preeclampsia. Am J Obstet Gynecol 1990;162:358–362.
58.
Nova A, Sibai BM, Barton JR, Mercer BM, Mitchell MD: Maternal plasma level of endothelin is increased in preeclampsia. Am J Obstet Gynecol 1991;165:724–727.
59.
Eremina V, Quaggin SE: The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 2004;13:9–15.
60.
Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–658.
61.
Banks RE, Forbes MA, Searles J, Pappin D, Canas B, Rahman D, Kaufmann S, Walters CE, Jackson A, Eves P, Linton G, Keen J, Walker JJ, Selby PJ: Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1. Mol Hum Reprod 1998;4:377–386.
62.
Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–683.
63.
Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, Uzan S, Rondeau E: Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004;50:1702–1703.
64.
Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, Blink AL, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Urinary placental growth factor and risk of preeclampsia. JAMA 2005;293:77–85.
65.
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427–434.
66.
Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, Pinedo HM, Hoekman K: Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 2002;22:1500–1505.
67.
Kitamoto Y, Takeya M, Tokunaga H, Tomita K: Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney. Tohoku J Exp Med 2001;195:43–54.
68.
Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt1) induces proteinuria. J Biol Chem 2003;278:12605–12608.
69.
Roberts WG, Palade GE: Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995;108:2369–2379.
70.
Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M: Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992;267:19027–19030.
71.
Gougos A, St Jacques S, Greaves A, O’Connell PJ, d’Apice AJ, Buhring HJ, Bernabeu C, van Mourik JA, Letarte M: Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol 1992;4:83–92.
72.
McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, et al: Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345–351.
73.
Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, Husain M, Letarte M: A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005;96:684–692.
74.
Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D’Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642–649.
75.
Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992–1005.
76.
Epstein FH: Late vascular effects of toxemia of pregnancy. N Engl J Med 1964;271:391–395.
77.
Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA: Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005;366:1797–1803.
78.
Smith GC, Pell JP, Walsh D: Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 2001;357:2002–2006.
79.
Irgens HU, Reisaeter L, Irgens LM, Lie RT: Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. Br Med J 2001;323:1213–1217.
80.
Cohn BA, Cirillo PM, Christianson RE, van den Berg BJ, Siiteri PK: Placental characteristics and reduced risk of maternal breast cancer. J Natl Cancer Inst 2001;93:1133–1140.
81.
Vatten LJ, Romundstad PR, Trichopoulos D, Skjaerven R: Pre-eclampsia in pregnancy and subsequent risk for breast cancer. Br J Cancer 2002;87:971–973.
82.
Paltiel O, Friedlander Y, Tiram E, Barchana M, Xue X, Harlap S: Cancer after pre-eclampsia: follow up of the Jerusalem perinatal study cohort. Br Med J 2004;328:919.
83.
Aagaard-Tillery KM, Stoddard GJ, Holmgren C, Lacoursiere DY, Fraser A, Mineau GP, Varner MW: Preeclampsia and subsequent risk of cancer in Utah. Am J Obstet Gynecol 2006;195:691–699.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.